Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AL01811
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : $722.5 million
Deal Type : Collaboration
Details : The collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders to develop and commercialize AL01811, an oral disease modifying treatment for patients with Parkinson’s diseas...
Product Name : AL01811
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
June 06, 2022
Lead Product(s) : AL01811
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : $722.5 million
Deal Type : Collaboration
Reset All
